Liver inflammation and steatosis are fundamental pathological changes that contribute to the development of systemic insulin resistance in obesity. However, the molecular and cellular events that initiate and propagate obesity-related non-alcoholic fatty liver disease (NAFLD) remain unclear. We reported that neutrophil elastase (NE) knockout (KO) mice are resistant to a high-fat diet (HFD)-induced systemic inflammation, fatty liver, and insulin resistance. HFD feeding of WT mice for only a few days increases proinflammatory neutrophil production preceding vascular leakage, leukocyte infiltration and steatosis in the liver. Based on our preliminary data, we hypothesize that inhibition of NE prevents HFD-induced proinflammatory neutrophil production via altering NAD-dependent deacetylase Sirtuin 1 (Sirt1) signaling pathway in neutrophils. Inhibition of NE also increases the levels of high-molecular-weight adiponectin that activates AMP-kinase (AMPK) and fatty acid oxidation, thus attenuating HFD-induced steatosis in the liver. In addition, inhibition of NE also ameliorated high-fat high-carb diet (HFHCD)- induced steatosis, nonalcoholic steatohepatitis (NASH) and collagen deposition in the liver. In this proposal, we will evaluate if Sirt1 in neutrophils and the adiponectin ? AMPK pathway in the liver are required for the beneficial effects of NE inhibition on diet-induced neutrophil phenotypic changes, inflammatory liver damage and steatosis. Successful completion of this project will shed new light on molecular and cellular mechanisms by which inhibition of NE prevent obesity-related NAFLD and insulin resistance.

Public Health Relevance

Obesity is the primary cause of non-alcoholic fatty liver disease (NAFLD). This project is designed to understand the molecular mechanism by which neutrophil elastase (NE), a protein degrading enzyme produced by neutrophils, contributes to the development of obesity-related NAFLD. This study will provide evidence and molecular mechanisms by which inhibition of NE as a novel therapeutic strategy for obesity-related NAFLD.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
High Priority, Short Term Project Award (R56)
Project #
1R56DK121142-01A1
Application #
10017709
Study Section
Integrative Nutrition and Metabolic Processes Study Section (INMP)
Program Officer
Doo, Edward
Project Start
2019-09-15
Project End
2020-08-31
Budget Start
2019-09-15
Budget End
2020-08-31
Support Year
1
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Boston University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118